References
- Angela V., Jackle P., David H. J. Myasthenia gravis. Lancet 2001; 357: 2122–2128
- Grob D., Simpson D., Mitsumoto H., Hoch B., Mokhtarian F., Bender A., Greenberg M., Koo A., Nakayama S. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995; 45: 338–344
- Karussis D. M., Lehmann D., Brenner T., Wirguin I., Mizrachi-Koll R., Sicsic C., Abramsky O. Immunomodulation of experimental autoimmune myasthenia gravis with Linomide. Journal of Neuroimmunology 1994; 55: 187–93
- Kong D. L., Chen C. Z., Lin E. F., Yu Y. T. Clinical trials of type I and in vitro studies of type II immunoadsorbents for systemic lupus erythematosus therapy. Artificial Organs 1998; 22(8)644–650
- Lindstrom J. M. Acetylcholine receptors myasthenia. Muscle & Nerve 2000; 453–477
- Masaharu T., Seiichi O., Miwako N., Hiroaki Yoshikawa. Myasthenogenic significance of synthetic a-subunit peptide 183–200 of Torpedo californica and human acetylcholine receptor. Journal of the Neuronological Sciences 1988; 85: 121–129
- Premkumar C., Mathildle P., Deng C. S. Animal models of myasthenia gravis. Clin. Immuno. 2000; 94(2)75–87
- Shibuya N., Sato T., Osame M., Takegami T., Doi S., Kawanami S. Immunoadsorption therapy for myasthenia gravis. J. Neuro. Neurosur. Ps. 1994; 57: 578–581
- Yan W. R., Yu Y. T., Yang L. Studies on new immunoadsorbent for myasthenia gravis. Chemical Journal of Chinese Universities 2002; 23(10)1887–1890
- Yoshida M., Tamura Y., Yamada Y., Yamawaki N., Yamashita Y., Immusorba T. R., Immusorba P. H. Basics of design and features of functions. Ther. Apher. 2000; 4(2)127–134